GlaxoSmithKline (GSK) is facing fresh allegations of corruption, following reported incidents in China and Iraq. Polish authorities have launched a criminal investigation against the UK's biggest drugmaker for allegedly bribing doctors to promote its lung drug Seretide, also known as Advair, which has worldwide sales of around $8 billion a year.
U.S. biotechnology firm Amgen, the world's largest, is ending its agreement with the U.K. drugmaker GlaxoSmithkline for the marketing of its osteoporosis drug in some regions outside the U.S..
U.K. drugmaker GlaxoSmithKine (GSK), already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the company has confirmed.
The latest controversy involves claims that GSK hired Iraqi government-employed physicians and pharmacists as paid sales representatives to improperly boost use of its products.
GlaxoSmithKline (GSK), the UK's largest pharmaceutical company, has provisionally withdrawn its marketing authorization application to the European Medicines Agency (EMA) for the combined use of Tafinlar (also known as dabrafenib, Mekinist, or trametinib).
British drugmaker GlaxoSmithKline (GSK) said it has successfully increased its stake in its publicly-listed Indian pharmaceuticals subsidiary GlaxoSmithKline Pharmaceuticals Limited from 50.7% to 75%. The Indian firm will remain publicly-listed.
UK drugmaker Glaxo SmithKline has said it would cease offering financial incentives to doctors to promote its products through speaking engagements, for example. The company also will stop linking remuneration of its sales representatives to the number of prescriptions generated. Starting from the beginning of 2015 it also will no longer pay healthcare professionals to attend medical conferences.
British Prime Minister David Cameron raised GlaxoSmithKline's problems in China - where it is being investigated for alleged bribery - with political leaders on Monday as the drugmaker emphasized its commitment to doing business there.
Glaxo SmithKline (GSK) has announced plans to invest £25 million in expanding its active ingredient formulating plant at Montrose, Scotland. The UK drug maker said it would locate production of four unspecified new entities at the site, where it is receiving more than £3 million in financial support from the local government of Angus and the business development agency Scottish Enterprise.
GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds ($1.5 billion) and focus its consumer health business on global products.
The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3% from a year ago.
Britain's competition body accused GlaxoSmithKline of market abuse for striking deals with three generic drugmakers that paid them to delay launching cheap copies of its antidepressant Seroxat.
GSK, Britain's biggest drugmaker, said it believed it had acted lawfully. If it is found to have broken the law, it could be fined up to 10% of its worldwide turnover, which amounted to 26.4 billion pounds ($40.4 billion) in 2012.